α6 Integrin Cleavage: Sensitizing human prostate cancer to ionizing radiation

International Journal of Radiation Biology

Volumn 83, Issue 11-12, 2007, Pages 761-767

  Pawar, Sangita C ^a,c   Dougherty, Shona ^a,b   Pennington, Michael E ^a,c   Demetriou, Manolis C ^a,c   Stea, B Dino ^b   Dorr, Robert T ^a   Cress, Anne E ^a,b,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Growth delay; Integrin; Ionizing radiation; Prostate cancer; Tumor cell kill; Tumor doubling time; Tumor growth inhibition

Indexed keywords

ALPHA INTEGRIN; ALPHA6 INTEGRIN; PRIMER DNA; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; GENE MUTATION; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; METABOLISM; MOUSE MUTANT; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; INTEGRIN ALPHA6; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; MUTATION; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RECOMBINANT PROTEINS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 36849052354     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000701633135     Document Type: Article

References (24)

1. Barcellos-Hoff MH. 1993. Radiation-induced transforming growth factor beta and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Research 53:3880-3886.
2. Barcellos-Hoff MH, Park C, Wright EG. 2005. Radiation and the microenvironment-tumorigenesis and therapy. Nature Reviews Cancer 5:867-875.
3. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. 1991. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Research 51:4845-4852.
4. Brouty-Boye D, Raux H, Azzarone B, Tamboise A, Tamboise E, Beranger S, Magnien V, Pihan I, Zardi L, Israel L. 1991. Fetal myofibroblast-like cells isolated from post-radiation fibrosis in human breast cancer. International Journal of Cancer 47:697-702.
5. Chen X, Gumbiner BM. 2006. Crosstalk between different adhesion molecules. Current Opinion in Cell Biology 18:572-578.
6. Cordes N. 2006. Cell adhesion-mediated radiation resistance: The role of integrins and integrin proximal protein. In: Cress AW, Nagle RB, R. J. A. a. W. G. Jiang. Cell adhesion and cytoskeletal molecules in metastasis Cancer Metastasis-Biology and Treatment, Volume 9, Springer, Dordrecht, The Netherlands. Editors RJ Ablin and WG Jiang. pp 141-162.
7. Cordes N, Meineke V. 2003. Cell adhesion-mediated radio-resistance (CAM-RR). Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlentherapie und Onkology 179:337-344.
8. Damiano JS. 2002. Integrins as novel drug targets for overcoming innate drug resistance. Current Cancer Drug Targets 2:37-43.
9. Davis TL, Rabinovitz I, Futscher BW, Schnolzer M, Burger F, Liu Y, Kulesz-Martin M, Cress AE. 2001. Identification of a novel structural variant of the alpha 6 integrin. Journal of Biological Chemistry 276:26099-26106.
10. Demetriou MC, Pennington ME, Nagle RB, Cress AE. 2004. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Experimental Cell Research 294:550-558.
11. Hehlgans S, Haase M, Cordes N. 2007. Signalling via integrins: Implications for cell survival and anticancer strategies. Biochimica et Biophysica Acta 1775:163-180.
12. Hummerich J, Werle-Schneider G, Popanda O, Celebi O, Chang-Claude J, Kropp S, Mayer C, Debus J, Bartsch H, Schmezer P. 2006. Constitutive mRNA expression of DNA repair-related genes as a biomarker for clinical radio-resistance: A pilot study in prostate cancer patients receiving radiotherapy. International Journal of Radiation Biology 82:593-604.
13. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics, 2007. CA A Cancer Journal for Clinicians 57:43-66.
14. Kremer CL, Schmelz M, Cress AE. 2006. Integrin-dependent amplification of the G2 arrest induced by ionizing radiation. Prostate 66:88-96.
15. Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA. 2000. Higher than standard radiation doses (> or=72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics 46:567-574.
16. Livsey JE, Wylie JP, Swindell R, Khoo VS, Cowan RA, Logue JP. 2004. Do differences in target volume definition in prostate cancer lead to clinically relevant differences in normal tissue toxicity? International Journal of Radiation Oncology, Biology, Physics 60:1076-1081.
17. Lotan Y, Stanfield J, Cho LC, Sherwood JB, Abdel-Aziz KF, Chang CH, Forster K, Kabbani W, Hsieh JT, Choy H, Timmerman R. 2006. Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model. Journal of Urology 175:1932-1936.
18. Parker W, Patrocinio H. 2005. Practical aspects of inverse-planned intensity-modulated radiation therapy for prostate cancer: A radiation treatment planner's perspective. Canadian Journal of Urology 12(Suppl 2):48-52.
19. Pawar SC, Demetriou MC, Nagle RB, Bowden GT, Cress AE. 2007. Integrin alpha6 cleavage: A novel modification to modulate cell migration. Experimental Cell Research 313:1080-1089.
20. Remy J, Wegrowski J, Crechet F, Martin M, Daburon F. 1991. Long-term overproduction of collagen in radiation-induced fibrosis. Radiation Research 125:14-19.
21. Schmelz M, Cress AE, Scott KM, Burger F, Cui H, Sallam K, McDaniel KM, Dalkin BL, Nagle RB. 2002. Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia 4:243-254.
22. Tamura RN, Rozzo C, Starr L, Chambers J, Reichardt LF, Cooper HM, Quaranta V. 1990. Epithelial integrin alpha 6 beta 4: Complete primary structure of alpha 6 and variant forms of beta 4. Journal of Cell Biology 111:1593-1604.
23. Tran NL, Nagle RB, Cress AE, Heimark RL. 1999. N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with Stromal cells. American Journal of Pathology 155:787-798.
24. Valdagni R, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T, Fiorino C, Nahum A. 2005. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiotherapy & Oncology 75:74-82.